Adverum Biotechnologies Provides 2018 Outlook
Adverum Biotechnologies, Inc. (ADVM)
Last adverum biotechnologies, inc. earnings: 3/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
adverum.gcs-web.com/investor-overview
Company Research
Source: GlobeNewswire
MENLO PARK, Calif., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, today reviewed recent progress and provided an outlook for 2018. “In 2017, our newly-assembled team achieved our stated goal of transforming Adverum into a clinical-stage company,” said Amber Salzman, Ph.D., president and chief executive officer of Adverum Biotechnologies. “We were focused on our corporate milestones, and last month we began patient enrollment in ADVANCE, our Phase 1/2 clinical trial of ADVM-043 in alpha-1 antitrypsin deficiency. We expect to report preliminary data from the ADVANCE trial in the second half of 2018. In addition, we are accelerating the development of our pipeline of gene therapies and plan to submit two investigational new drug applications with the FDA in the second half of 2018, for ADVM-022 in wet AMD and ADVM-053 in hereditary angioedema. With
Show less
Read more
Impact Snapshot
Event Time:
ADVM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADVM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADVM alerts
High impacting Adverum Biotechnologies, Inc. news events
Weekly update
A roundup of the hottest topics
ADVM
News
- Gene Therapies in Ophthalmology Market to Register Immense Growth at a CAGR of 57.8% by 2034 | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year? [Yahoo! Finance]Yahoo! Finance
- Down -29.25% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM) [Yahoo! Finance]Yahoo! Finance
- Adverum Biotechnologies, Inc. (NASDAQ: ADVM) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- US Retinal Specialists Highlight the Greatest Opportunity for Gene Therapies [Yahoo! Finance]Yahoo! Finance
ADVM
Earnings
- 11/9/23 - Miss
ADVM
Sec Filings
- 4/1/24 - Form EFFECT
- 3/27/24 - Form EFFECT
- 3/21/24 - Form S-3
- ADVM's page on the SEC website